Top

Published in:

Open Access 02-09-2023 | Benign Prostatic Hypertrophy | Original Article

Tomato lipidic extract plus selenium decrease prostatic hyperplasia, dihydrotestosterone and androgen receptor expression versus finasteride in rats

Authors: David Julian Arias-Chávez, Patrick Mailloux-Salinas, Jessica Ledesma-Aparicio, Elihu Campos-Pérez, Omar Noel Medina-Campos, José Pedraza-Chaverri, Guadalupe Bravo

Published in: World Journal of Urology | Issue 10/2023

Abstract

Purpose

Evaluate the therapeutic effect of a tomato lipidic extract (STE) in combination with selenium (Se) on rats with prostatic hyperplasia (PH) and to observe its possible mechanisms of action and synergism versus finasteride.

Materials and methods

54 male Wistar rats of nine weeks old were divided in Control (C), PH, Finasteride (F), STE, Se, F + STE, F + Se, STE + Se and F + STE + Se with testosterone enanthate (except C). After 4 weeks of treatment administration, prostate weight, bladder weight, diuresis, prooxidant and antioxidant activity, dihydrotestosterone (DHT), androgen receptor (AR) expression and anatomopathological analysis were determined.

Results

STE + Se decreased prostate weight 53.8% versus 28% in F group, also STE + Se decreased significatively glandular hyperplasia, prooxidant activity, DHT and AR expression and increased diuresis and antioxidant activity versus finasteride which increased MDA in prostate.

Conclusions

These results demonstrate a greater therapeutic and beneficial effect of tomato lipidic extract in combination with Se in young rats with PH with respect to finasteride without increase prooxidant activity.

Available only for authorised users

Chughtai B, Forde JC, Thomas DD, Laor L, Hossack T, Woo HH, Te AE, Kaplan SA (2016) Benign prostatic hyperplasia. Nat Rev Dis Primers 5(2):16031. https://doi.org/10.1038/nrdp.2016.31CrossRef

Blankstein U, Van Asseldonk B, Elterman DS (2016) BPH update: medical versus interventional management. Can J Urol 23(Suppl 1):10–15PubMed

Schauer IG, Rowley DR (2011) The functional role of reactive stroma in benign prostatic hyperplasia. Differentiation 82(4–5):200–210. https://doi.org/10.1016/j.diff.2011.05.007CrossRefPubMedPubMedCentral

D’Amico R, Genovese T, Cordaro M, Siracusa R, Gugliandolo E, Peritore AF et al (2021) Palmitoylethanolamide/baicalein regulates the androgen receptor signaling and NF-κB/Nrf2 pathways in benign prostatic hyperplasia. Antioxidants 10(7):1014. https://doi.org/10.3390/antiox10071014CrossRefPubMedPubMedCentral

Vickman RE, Franco OE, Moline DC, Vander Griend DJ, Thumbikat P, Hayward SW (2020) The role of the androgen receptor in prostate development and benign prostatic hyperplasia: a review. Asian J Urol 7(3):191–202. https://doi.org/10.1016/j.ajur.2019.10.003CrossRefPubMed

Langan RC (2019) Benign Prostatic Hyperplasia. Primary Care Clin Office Pract 46(2):223–232. https://doi.org/10.1016/j.pop.2019.02.003CrossRef

Traish AM (2020) Post-finasteride syndrome: a surmountable challenge for clinicians. Fertil Steril 113(1):21–25. https://doi.org/10.1016/j.fertnstert.2019.11.030CrossRefPubMed

Allkanjari O, Vitalone A (2015) What do we know about phytotherapy of benign prostatic hyperplasia? Life Sci 1(126):42–56. https://doi.org/10.1016/j.lfs.2015.01.023CrossRef

Cicero AFG, Allkanjari O, Busetto GM, Cai T, Larganà G, Magri V et al (2019) Nutraceutical treatment and prevention of benign prostatic hyperplasia and prostate cancer. Arch Ital Urol Androl 91(3):139–152. https://doi.org/10.4081/aiua.2019.3.139CrossRef

10.

Kumar M, Tomar M, Bhuyan DJ, Punia S, Grasso S, Sá AGA et al (2021) Tomato (Solanum lycopersicum L.) seed: a review on bioactives and biomedical activities. Biomed Pharmacother. 142:112018. https://doi.org/10.1016/j.biopha.2021.112018CrossRefPubMed

11.

Zhang X, Wang Q, Neil B, Chen X (2010) Effect of lycopene on androgen receptor and prostate-specific antigen velocity. Chin Med J 123(16):2231–2236PubMed

12.

Bodnar M, Konieczka P, Namiesnik J (2012) The properties, functions, and use of selenium compounds in living organisms. J Environ Sci Health 30(3):225–252. https://doi.org/10.1080/10590501.2012.705164CrossRef

13.

Ullah H, Liu G, Yousaf B, Ali MU, Abbas Q, Munir MAM, Mian MM (2018) Developmental selenium exposure and health risk in daily foodstuffs: a systematic review and meta-analysis. Ecotoxicol Environ Saf 149:291–306. https://doi.org/10.1016/j.ecoenv.2017.11.056CrossRefPubMed

14.

Minutoli L, Bitto A, Squadrito F, Marini H, Irrera N, Morgia G et al (2013) Serenoa repens, lycopene and selenium: a triple therapeutic approach to manage benign prostatic hyperplasia. Curr Med Chem 20(10):1306–1312. https://doi.org/10.2174/0929867311320100007CrossRefPubMed

15.

Morgia G, Cimino S, Favilla V, Russo GI, Squadrito F, Mucciardi G et al (2013) Effects of Serenoa repens, selenium and lycopene (Profluss®) on chronic inflammation associated with benign prostatic hyperplasia: results of “FLOG” (Flogosis and Profluss in Prostatic and Genital Disease), a multicentre Italian study. Int Braz J Urol 39(2):214–221. https://doi.org/10.1590/S1677-5538.IBJU.2013.02.10CrossRefPubMed

16.

Shoieb SM, Esmat A, Khalifa AE, Abdel-Naim AB (2018) Chrysin attenuates testosterone-induced benign prostate hyperplasia in rats. Food Chem Toxicol 111:650–659. https://doi.org/10.1016/j.fct.2017.12.017CrossRefPubMed

17.

Wang L, Hou Y, Wang R, Pan Q, Li D, Yan H, Sun Z (2021) Inhibitory effect of astaxanthin on testosterone-induced benign prostatic hyperplasia in rats. Mar Drugs 19(12):652. https://doi.org/10.3390/md19120652CrossRefPubMedPubMedCentral

18.

Gallo E, Maggini V, Lombardi N, Crescioli G, Sivelli F, Vannacci A, Firenzuoli F (2022) Serenoa repens induced erectile dysfunction: Underdiagnosis and phytovigilance. Br J Clin Pharmacol 88(5):2441–2443. https://doi.org/10.1111/bcp.15129CrossRefPubMed

19.

Azimi H, Khakshur AA, Aghdasi I, Fallah-Tafti M, Abdollahi M (2012) A review of animal and human studies for management of benign prostatic hyperplasia with natural products: perspective of new pharmacological agents. Curr Drug Targets Inflamm Allergy 11(3):207–221. https://doi.org/10.2174/187152812800392715CrossRef

20.

Kang DI, Chung JI (2013) Current status of 5α-reductase inhibitors in prostate disease management. Korean J Urol 54(4):213–219. https://doi.org/10.4111/kju.2013.54.4.213CrossRefPubMedPubMedCentral

21.

Foo KT (2019) What is a disease? What is the disease clinical benign prostatic hyperplasia (BPH)? World J Urol 37(7):1293–1296. https://doi.org/10.1007/s00345-019-02691-0CrossRefPubMedPubMedCentral

22.

Devlin CM, Simms MS, Maitland NJ (2021) Benign prostatic hyperplasia—what do we know? BJU Int 127(4):389–399. https://doi.org/10.1111/bju.15229CrossRefPubMed

23.

Silva SA, Gobbo MG, Pinto-Fochi ME, Rafacho A, Taboga SR, Almeida EA et al (2015) Prostate hyperplasia caused by long-term obesity is characterized by high deposition of extracellular matrix and increased content of MMP-9 and VEGF. Int J Exp Pathol 96(1):21–30. https://doi.org/10.1111/iep.12107CrossRefPubMed

24.

Nandy PR, Saha S (2016) Association between components of metabolic syndrome and prostatic enlargement: an Indian perspective. Med J Armed Forces India 72(4):350–355. https://doi.org/10.1016/j.mjafi.2016.07.005CrossRefPubMedPubMedCentral

25.

Wang H, Leung LK (2010) The carotenoid lycopene differentially regulates phase I and II enzymes in dimethylbenz[a]anthracene-induced MCF-7 cells. Nutrition 26(11–12):1181–1187. https://doi.org/10.1016/j.nut.2009.11.01CrossRefPubMed

Title: Tomato lipidic extract plus selenium decrease prostatic hyperplasia, dihydrotestosterone and androgen receptor expression versus finasteride in rats
Authors: David Julian Arias-Chávez
Patrick Mailloux-Salinas
Jessica Ledesma-Aparicio
Elihu Campos-Pérez
Omar Noel Medina-Campos
José Pedraza-Chaverri
Guadalupe Bravo
Publication date: 02-09-2023
Publisher: Springer Berlin Heidelberg
Keywords: Benign Prostatic Hypertrophy
Benign Prostatic Hypertrophy
Finasteride
Stanolone
Androgens
Testosterone
Published in: World Journal of Urology / Issue 10/2023
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-023-04558-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Tomato lipidic extract plus selenium decrease prostatic hyperplasia, dihydrotestosterone and androgen receptor expression versus finasteride in rats

Abstract

Purpose

Materials and methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2023

Crystalluria in adolescent and adult patients with congenital heart disease

Prognostic value of pretreatment inflammatory markers in localised prostate cancer before radical prostatectomy

Correction: Is cribriform pattern in prostate biopsy a risk factor for metastatic disease on 68Ga-PSMA-11 PET/CT?

Computer tomography-based shape of tumor contour and texture of tumor heterogeneity are independent prognostic indicators for clinical T1b–T2 renal cell carcinoma

Letter to the editor for the article “Molecular urothelial tumor cell subtypes remain stable during metastatic evolution”

En bloc resection of bladder tumour: the rebirth of past through reminiscence